Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB

Trial Profile

Prospective, Randomized, Blinded Phase II Pharmacokinetic/Pharmacodynamic Study of the Efficacy and Tolerability of Levofloxacin in Combination With Optimized Background Regimen for the Treatment of MDR-TB

Completed
Phase of Trial: Phase II

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs Levofloxacin (Primary) ; Antituberculars
  • Indications Pulmonary tuberculosis
  • Focus Therapeutic Use
  • Acronyms Opti-Q
  • Most Recent Events

    • 27 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 27 Feb 2017 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017.
    • 27 Feb 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top